ReShape Lifesciences Share Price OTC Markets

Equities

RSLS

US7611236032

Advanced Medical Equipment & Technology

End-of-day quote OTC Markets 03:30:00 08/07/2021 am IST 5-day change 1st Jan Change
5.09 USD +23.84% Intraday chart for ReShape Lifesciences -.--% -.--%
Sales 2022 1.12Cr 94Cr Sales 2023 86.78L 72Cr Capitalization 46.24L 39Cr
Net income 2022 -4.6Cr -383.94Cr Net income 2023 -1.1Cr -92Cr EV / Sales 2022 -0.04 x
Net cash position 2022 36.84L 31Cr Net cash position 2023 41.97L 35Cr EV / Sales 2023 0.05 x
P/E ratio 2022
-0.06 x
P/E ratio 2023
-0.13 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 88.83%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 59 01/20/01
Director of Finance/CFO 63 15/21/15
Compliance Officer - -
Members of the board TitleAgeSince
Director/Board Member 66 01/16/01
Chairman 70 01/15/01
Director/Board Member 70 15/21/15
More insiders
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
More about the company